FDA 483 - Medtronic Puerto Rico Operations Co. - June 13, 2006

The FDA conducted an inspection of Medtronic Puerto Rico Operations Co., a medical device manufacturer located in Juncos, Puerto Rico, from March 13 to June 13, 2006. The inspection revealed several significant compliance issues related to production and process controls, which were documented in the FDA Form 483.

Key violations included inadequate validation of software used in the manufacturing of Paradigm external insulin pumps. The software validation failed to demonstrate that it met specified requirements, lacked testing for certain error messages, and did not provide written justifications for omitting specific tests. Additionally, the validation process for the automated adhesive dispensing and assembly processes was found lacking, as it did not adequately address equipment setup failures or the impact of reduced sample sizes on validation outcomes.

Further observations noted that certain test equipment was unsuitable for its intended purposes, as it did not ensure consistent pressure application during sensor calibration. Moreover, procedural deviations were identified, such as the failure to generate required deviation authorizations for non-conforming torque tubes.

The FDA also highlighted deficiencies in the verification and validation of corrective and preventive actions (CAPA). Specifically, there was no documented evidence to confirm that new preventive maintenance procedures would effectively prevent calibration failures.

Medtronic is required to address these issues by conducting thorough internal audits to identify and rectify all violations of quality system requirements, ensuring compliance with FDA regulations.